[{"data":1,"prerenderedAt":222},["ShallowReactive",2],{"drug-posaconazole":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":44,"contraindications":98,"warnings":108,"renal":116,"monitoring":117,"interactions":118,"review":119,"examples":122,"atc":135,"iran":137,"usApproval":161,"links":167,"populations":186},"posaconazole",1,{"fa":7,"en":8},"پوساکونازول","Posaconazole","anti-infectives",{"fa":11,"en":12},"ضدقارچ آزولی","Azole antifungal",[14],{"name":15,"market":16},"Noxafil","US",[18,19,7],"noxafil","نوکسافیل",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"dr-100","tablet","oral","100 mg delayed-release tablet (NOT interchangeable with suspension)",{"amount":27,"unit":28,"perUnit":23,"scored":29},100,"mg",false,[16],[32],{"source":33,"section":34},"fda-noxafil","3",{"id":36,"form":37,"route":24,"label":38,"concentration":39,"markets":41,"refs":42},"susp-40","suspension","40 mg\u002FmL oral suspension (NOT interchangeable with tablets)",{"amount":40,"unit":28,"perVolumeMl":5},40,[16],[43],{"source":33,"section":34},[45,73,85],{"id":46,"disease":47,"label":48,"population":51,"type":56,"unit":28,"dose":57,"refs":59,"allowedFormulations":62,"notes":63},"proph","invasive-fungal",{"fa":49,"en":50},"پیشگیری از آسپرژیلوس و کاندیدا (سرکوب ایمنی شدید) — قرص: روز اول ۳۰۰ mg دو بار، سپس ۳۰۰ mg یک بار در روز","Aspergillus\u002FCandida prophylaxis (severe immunosuppression) — tablets: 300 mg twice on day 1, then 300 mg once daily",{"minAge":52,"minWeightKg":55},{"value":53,"unit":54},13,"year",40.01,"fixed",{"perDose":58,"dosesPerDay":5},300,[60],{"source":33,"section":61},"2.2, Table 1",[22],[64],{"text":65,"refs":68},{"fa":66,"en":67},"روز اول بارگذاری ۳۰۰ mg دو بار. قرص آهسته‌رهش و سوسپانسیون جایگزین هم نیستند.","Day 1 loading 300 mg twice. Delayed-release tablets and suspension are not interchangeable.",[69,71],{"source":33,"section":70},"2.2",{"source":33,"section":72},"2.9",{"id":74,"disease":47,"label":75,"population":78,"type":56,"unit":28,"dose":81,"refs":82,"allowedFormulations":84},"asperg",{"fa":76,"en":77},"درمان آسپرژیلوز تهاجمی — قرص: روز اول ۳۰۰ mg دو بار، سپس ۳۰۰ mg یک بار (۶ تا ۱۲ هفته)","Invasive aspergillosis — tablets: 300 mg twice on day 1, then 300 mg once daily (6–12 weeks)",{"minAge":79},{"value":80,"unit":54},18,{"perDose":58,"dosesPerDay":5},[83],{"source":33,"section":61},[22],{"id":86,"disease":47,"label":87,"population":90,"type":56,"unit":28,"dose":92,"refs":95,"allowedFormulations":97},"proph-susp",{"fa":88,"en":89},"پیشگیری — سوسپانسیون: ۲۰۰ mg (۵ mL) سه بار در روز","Prophylaxis — suspension: 200 mg (5 mL) three times daily",{"minAge":91},{"value":53,"unit":54},{"perDose":93,"dosesPerDay":94},200,3,[96],{"source":33,"section":61},[36],[99],{"id":100,"severity":101,"text":102,"refs":105},"ci","block",{"fa":103,"en":104},"حساسیت به پوساکونازول یا سایر آزول‌ها؛ سیرولیموس؛ پیموزاید و کینیدین (QT)؛ استاتین‌های وابسته به CYP3A4 (سیمواستاتین، لواستاتین، آتورواستاتین)؛ آلکالوئیدهای ارگوت؛ ونتوکلاکس در شروع درمان CLL.","Hypersensitivity to posaconazole or other azoles; sirolimus; pimozide and quinidine (QT); CYP3A4-metabolised statins (simvastatin, lovastatin, atorvastatin); ergot alkaloids; venetoclax at initiation for CLL.",[106],{"source":33,"section":107},"4",[109],{"text":110,"refs":113},{"fa":111,"en":112},"طولانی شدن QT؛ سمیت کبد؛ تداخل زیاد با داروهای CYP3A4.","QT prolongation; hepatotoxicity; many CYP3A4 drug interactions.",[114],{"source":33,"section":115},"5",[],[],[],{"status":120,"reviewer":121,"date":121},"unverified",null,[123,128,131],{"regimen":46,"formulation":22,"input":124,"expect":127},{"ageYears":125,"weightKg":126},50,70,{"perDose":58,"tabletsPerDoseRounded":94},{"regimen":74,"formulation":22,"input":129,"expect":130},{"ageYears":125,"weightKg":126},{"perDose":58,"tabletsPerDoseRounded":94},{"regimen":86,"formulation":36,"input":132,"expect":133},{"ageYears":125,"weightKg":126},{"perDose":93,"mlPerDose":134},5,[136],"J02AC04",{"status":138,"forms":139,"refs":156},"registered",[140,144,148,152],{"code":141,"en":142,"fa":143},"08519","POSACONAZOL 40MG\u002FML SUSP","سوسپانسیون پوساکونازول ۴۰ میلی‌گرم \u002F میلی‌لیتر",{"code":145,"en":146,"fa":147},"50722","POSACONAZOLE SUSPENSION ORAL 40 mg\u002F1mL 105 mL","سوسپانسیون خوراکی پوساکونازول ۴۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰۵ میلی‌لیتر",{"code":149,"en":150,"fa":151},"51840","POSACONAZOLE TABLET, DELAYED RELEASE ORAL 100 mg","قرص انتریک‌کوتد پوساکونازول ۱۰۰ میلی‌گرم",{"code":153,"en":154,"fa":155},"52742","POSACONAZOLE INJECTION, SOLUTION, CONCENTRATE PARENTERAL 300 mg\u002F16.7mL","کنسانتره محلول تزریقی پوساکونازول ۳۰۰ میلی‌گرم \u002F ۱۶٫۷ میلی‌لیتر",[157],{"source":158,"section":159,"url":160},"darooyab-generic","G-739\u002FPosaconazole","https:\u002F\u002Fwww.darooyab.ir\u002FG-739\u002FPosaconazole",{"kind":162,"refs":163,"id":166},"NDA",[164],{"source":33,"section":165},"SPL approval \u002F marketing category","NDA022003",[168,171,175,178,181,184],{"kind":169,"url":170,"label":166},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022003",{"kind":172,"url":173,"label":174},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84","FDA Noxafil",{"kind":176,"url":177,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607036.html",{"kind":176,"url":179,"label":180},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa616017.html","Posaconazole Injection",{"kind":182,"url":183,"label":136},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J02AC04",{"kind":185,"url":160,"label":8},"darooyab",{"pregnancy":187,"lactation":196,"pediatric":205,"geriatric":213},{"level":188,"text":189,"quote":192,"refs":193},"avoid",{"fa":190,"en":191},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on findings from animal data, Noxafil may cause fetal harm when administered to pregnant women.",[194],{"source":33,"section":195},"8.1",{"level":197,"text":198,"quote":201,"refs":202},"caution",{"fa":199,"en":200},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of posaconazole in human milk, the effects on the breastfed infant, or the effects on milk production.",[203],{"source":33,"section":204},"8.2",{"level":197,"text":206,"quote":209,"refs":210},{"fa":207,"en":208},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Treatment of Invasive Aspergillosis The safety and effectiveness of Noxafil (injection and delayed-release tablets) have been established for the treatment of invasive aspergillosis in pediatric patients 2 years of age and older .",[211],{"source":33,"section":212},"8.4",{"level":214,"text":215,"quote":218,"refs":219},"ok",{"fa":216,"en":217},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in the safety or effectiveness of Noxafil injection, Noxafil delayed-release tablets, and Noxafil oral suspension have been observed between geriatric patients and younger adult patients in the clinical trials; therefore, the recommended dosage in geriatric patients is the same as that for …",[220],{"source":33,"section":221},"8.5",1792191561859]